Nuances in the Management of Aggressive Lymphomas

November 6, 2016

Learning Objectives

  • Demonstrate increased understanding of the MOAs of targeted and immunotherapies agents in the treatment of primary and relapsed/refractory lymphomas, and their emerging role(s) in treatment regimens.
  • Identify potential adverse events that may be associated with newer targeted and immunotherapies and how such adverse events may be adequately addressed to optimize patient outcome.
  • Demonstrate an understanding of relevant clinical practice guidelines for lymphomas.
  • Evaluate emerging treatment data in primary and relapsed/refractory lymphomas and its potential impact in clinical practice.
Course summary
Available credit: 
  • 1.00 ACPE
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Attendance
  • 1.00 ANCC
Course opens: 
11/06/2016
Course expires: 
04/30/2017
Event starts: 
11/06/2016 - 8:30am
Event ends: 
11/06/2016 - 9:30am
Cost:
$0.00
Rating: 
0
Gaylord National Hotel
National Harbor, MD
United States

Available Credit

  • 1.00 ACPE
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Attendance
  • 1.00 ANCC

Price

Cost:
$0.00
Please login or register to take this course.